Correspondence to Letter to the Editor on “Genomic Biomarkers To Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights From the IMbrave150 Trial”

Authors

Sung Hwan Lee
Sun Young Yim
Ji Hoon Kim
Sunyoung S Lee
Ahmed O Kaseb
Peng Wei
Ju-Seog Lee

Publication Date

1-1-2025

Journal

Clinical Molecular Hepatology

DOI

10.3350/cmh.2024.0828

PMID

39355874

PMCID

PMC11791560

PubMedCentral® Posted Date

10-2-2024

PubMedCentral® Full Text Version

Post-print

Keywords

Biomarkers, Hepatocellular carcinoma, Immunotherapy, Liver cancer

Published Open-Access

yes

Recommended Citation

Lee, Sung Hwan; Yim, Sun Young; Kim, Ji Hoon; et al., "Correspondence to Letter to the Editor on “Genomic Biomarkers To Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights From the IMbrave150 Trial”" (2025). Faculty, Staff and Student Publications. 5139.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5139